ClinicalTrials.gg
CompletedNCT06191991Updated Feb 17, 2025

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

A Phase 1 interventional study of Atorvastatin and ALG-055009 in Healthy Volunteers, sponsored by Aligos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Aligos Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Parts 1 and 2, the drug-drug interaction (DDI) potential of ALG-055009 will be explored, where subjects will be assigned to receive multiple doses of ALG-055009 and 2 single doses of one of the following concomitant drugs: atorvastatin (Part 1), or rosuvastatin (Part 2, optional).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Aligos Therapeutics is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
  2. In the Investigator's opinion, the subject is able to understand and comply with protocol requirements, instructions, and protocol stated restrictions and is likely to complete the study as planned.
  3. Male or female between 18 and 65 years of age, extremes included.
  4. Female subjects must not be a woman of defined as:

    1. :

      A postmenopausal state is defined as no menses for at least 12 months without an alternative medical explanation, confirmed by a high follicle-stimulating hormone (FSH) level in the postmenopausal range at screening.

      OR

    2. Permanently sterile:

    Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

  5. Male subjects must agree to wear a condom during sexual intercourse and their female sexual partners should agree to use effective means of (Section 7.2.3). These contraceptive measures must be implemented, at a minimum, from the start of dosing until at least 90 days after the last dose.

    NOTE: Contraceptive use should be consistent with local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.

  6. Subjects must have a (BMI) of 18.0 to 32.0 kg/m2, extremes included.
  7. Subjects must be nonsmokers for at least 3 months prior to enrollment.
  8. Subjects must have a 12-lead (ECG) that meets the following criteria at screening:

    1. Heart rate between 40 and 100 beats per minute [bpm], extremes included;
    2. corrected for heart rate (QTc) according to Fridericia's formula (QTcF) \<450 ms (males) or \<470 ms (females);
    3. QRS interval \<120 ms;
    4. PR interval ≥110 to ≤220 ms;
    5. In addition to fulfilling the above ECG criteria, ECG morphology must have no abnormalities observed.
  9. Subjects must be deemed to be in good overall health by the Investigator on the basis of a medical evaluation that reveals the absence of any clinically significant abnormality and includes a physical examination, medical history, vital signs, and the results of blood chemistry, blood coagulation and hematology tests, and a urinalysis performed at screening.
  10. Subject must be willing and able to adhere to the Prohibited Medication requirements (Appendix B) and Special Precautions (Section 6.12).

Exclusion criteria

Exclusion Criteria:

  1. Subject with a) a medical history of thyroid disorder or b) abnormal thyroid stimulating hormone (TSH), free thyroxine (T4) or total triiodothyronine (T3) during screening, and Day -1 or c) known sensitivity to thyroid medications.
  2. The following laboratory values at screening are exclusionary:

    1. or AST > (ULN),
    2. Total >1.2× ULN, unless Gilbert's Syndrome is suspected
  3. Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation. This may include, but is not limited to, renal, cardiac, vascular, pulmonary, gastrointestinal, hepatologic, endocrine, neurologic, dermatologic, hematologic, rheumatologic, psychiatric, neoplastic, or metabolic disturbances.
  4. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease such as: angina, congestive heart failure, myocardial infarction, diastolic dysfunction, significant arrhythmia, coronary heart disease, abnormalities, moderate to severe valvular disease or uncontrolled hypertension. Evidence on ECG of heart block or bundle branch block, inclusive of first-degree AV block and incomplete bundle branch block, is also exclusionary.
  5. History of unexplained syncope.
  6. Subjects with a history of clinically significant (in the opinion of the Investigator) drug allergy such as, but not limited to, sulfonamides or drug allergy witnessed in previous studies with experimental drugs.
  7. Subjects with a recent (within 1 year of enrollment) history or current evidence of use of amphetamines, barbiturates, narcotic or other drugs of abuse/recreational drug use (including cannabis).
  8. Excessive use of alcohol defined as regular consumption of ≥14 standard drinks/week for women and ≥21 standard drinks/week for men (Chalasani et al. 2018). For current definition of a standard drink, please refer to the National Institute on Alcohol Abuse and Alcoholism website (https://www.niaaa.nih.gov/what-standard-drink).
  9. Unwilling to abstain from alcohol use for 1 week prior to start of study through end of study follow up.
  10. Positive results for urine drug screen, alcohol or cotinine test at screening and Day -1.
  11. Subjects with current:

    1. Hepatitis A virus infection (confirmed by hepatitis A antibody immunoglobulin M [IgM]).
    2. infection defined as presence of HBsAg or HBV core antibody.
    3. virus (HCV) infection (confirmed by HCV antibody and/or HCV RNA).
    4. Hepatitis E virus: Anti-HEV IgM-positive and/or detectable HEV RNA level.
    5. type 1 (HIV-1) or HIV-2 infection (confirmed by antibodies) at screening.
    6. Acute infection at the time of enrollment. If an acute infection is considered resolved prior to enrollment, the subject remains eligible.
  12. Male subjects who plan to father a child while enrolled in this study or within 90 days after the last dose of study drug.
  13. Subject receiving, or urgently requiring, any lipid lowering therapy (e.g., statins). Prior use (at least 1 month prior to screening) of lipid lowering therapy is not exclusionary.
  14. Subject who has taken or requires treatment with any disallowed therapies as noted in Prohibited Medications (Appendix B) and Special Precautions (Section 6.12) within 1 week or 5 half-lives (whichever is longer) before the planned first dose of study drug or during dosing; use of sensitive substrates, inhibitors/inducers of CYP3A4, inhibitors of OATP1B1, OATP1B3, and/or BCRP transporters (see Appendix B), within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study drug is prohibited.
  15. Consumption of grapefruit, grapefruit juice, and Seville oranges within 14 days prior to study drug administration.
  16. Consumption of apple or orange juice, citrus fruits, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and charbroiled meats within 7 days prior to study drug administration.
  17. Consumption of any food or drink/beverage containing quinine (e.g., tonic, bitter lemon, bitter alcoholic beverages containing quinine) within 24 hours prior to study drug administration.
  18. Consumption of any food or drink/beverage containing poppy seeds or codeine containing formulation within 72 hours of screening and admission to study site.
  19. Known or previous adverse events (AEs) with atorvastatin, rosuvastatin or other statins.
  20. Subjects who received an agent within 4 weeks (or 5 half-lives, whichever is longer) prior to enrollment.
  21. Subjects currently participating in another clinical or medical interventional research study.
  22. Subjects with any laboratory result that is considered clinically significant by the Investigator at screening. Abnormal values of ALT, AST, total bilirubin, TSH, free T4, and total T3 are exclusionary regardless of any clinical significance assessment by the Investigator (see Exclusion Criteria 1 and 2).
  23. Clinically significant abnormal vital signs (evaluated in the supine position after 5 minutes of rest), confirmed with retesting after at least 5 minutes of additional rest and at the discretion of the PI. Vital sign reference ranges to assess eligibility are as follows:

    1. Systolic blood pressure: >90 to ≤140 mmHg
    2. Diastolic blood pressure: ≥45 to ≤90 mmHg
    3. Pulse rate: ≥40 to ≤100 beats per minute
  24. Physical examination findings that are considered clinically significant in the opinion of the Investigator and likely to adversely impact study conduct and/or interpretation are exclusionary.
  25. Subjects who had major surgery (e.g., requiring general anesthesia) within 12 weeks before enrollment, or will not have fully recovered from surgery, or have surgery planned during the time the subject is expected to participate in the study, or within 4 weeks after the last dose of study drug.
  26. Subjects with renal dysfunction [e.g., estimated \<80 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration () formula]. CKD-EPI should not be corrected for subjects of African ancestry.
  27. Subject is an employee of the Sponsor, the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Atorvastatin with ALG-055009

    Single dose PO administration of 40 mg atorvastatin (Day 1), then a washout period of at least 2 days, followed by PO QD administration of 0.9 mg ALG-055009 for 14 days (Days 3-16) and single dose PO administration of 40 mg atorvastatin (Day 15).

    Drug: Atorvastatin · Drug: ALG-055009

  • Experimental
    Rosuvastatin with ALG-055009 (optional)

    Single dose PO administration of 10 mg rosuvastatin (Day 1), then a washout period of at least 4 days, followed by PO QD administration of 0.9 mg ALG-055009 for 11 days (Days 5-15) and single dose PO administration of 10 mg rosuvastatin (Day 11).

    Drug: ALG-055009 · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration time curve [AUC]

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: 23 days

  2. Time to maximum plasma concentration [Tmax]

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: 23 days

  3. Maximum plasma concentration [Cmax]

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: 23 days

  4. Minimum plasma concentration [Cmin]

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: 23 days

  5. C0 [predose]

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: 23 days

  6. Half-life [t1/2]

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: 23 days

  7. Area under the concentration time curve [AUC]

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: 22 days

  8. Time to maximum plasma concentration [Tmax]

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: 22 days

  9. Maximum plasma concentration [Cmax]

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: 22 days

  10. Minimum plasma concentration [Cmin]

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: 22 days

  11. C0 [predose]

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: 22 days

  12. Half-life [t1/2]

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: 22 days

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1

    Time frame: up to 23 days for part 1

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1

    Time frame: Up to 22 days for part 2

  3. Time to maximum plasma concentration [Cmax] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 23 days for part 1

  4. Minimum plasma concentration [Cmin] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable

    Time frame: up to 23 days for part 1

  5. Area under the concentration time curve [AUC] of ALG-055009 (ng/mL)PK

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 23 days for part 1

  6. Time to maximum plasma concentration [Tmax] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 23 days for part 1

  7. Half-life [t1/2] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 23 days for part 1

  8. Time to maximum plasma concentration [Cmax] of 2-hydroxy-atorvastatin (ng/mL)

    Pharmacokinetic parameters of 2-hydroxy-atorvastatin and applicable

    Time frame: up to 23 days for part 1

  9. Minimum plasma concentration [Cmin] of 2-hydroxy-atorvastatin (ng/mL)

    Pharmacokinetic parameters of 2-hydroxy-atorvastatin and applicable metabolites

    Time frame: up to 23 days for part 1

  10. Area under the concentration time curve [AUC] of 2-hydroxy-atorvastatin (ng/mL)

    Pharmacokinetic parameters of atorvastatin and applicable metabolites

    Time frame: up to 23 days for part 1

  11. Time to maximum plasma concentration [Tmax] of 2-hydroxy-atorvastatin (ng/mL)

    Pharmacokinetic parameters of 2-hydroxy-atorvastatin and applicable metabolites

    Time frame: up to 23 days for part 1

  12. Half-life [t1/2] of 2-hydroxy-atorvastatin (ng/mL)

    Time to maximum plasma concentration \[Cmax\] of ALG-055009 (ng/mL)

    Time frame: up to 23 days for part 1

  13. Minimum plasma concentration [Cmin] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 22 days for part 2

  14. Area under the concentration time curve [AUC] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 22 days for part 2

  15. Time to maximum plasma concentration [Tmax] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 22 days for part 2

  16. Half-life [t1/2] of ALG-055009 (ng/mL)

    Pharmacokinetic parameters of ALG-055009 and applicable metabolites

    Time frame: up to 22 days for part 2

  17. Time to maximum plasma concentration [Cmax] of rosuvastatin (ng/mL)

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: up to 22 days for part 2

  18. Minimum plasma concentration [Cmin] of rosuvastatin (ng/mL)

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: up to 22 days for part 2

  19. Area under the concentration time curve [AUC] of rosuvastatin (ng/mL)

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: up to 22 days for part 2

  20. Time to maximum plasma concentration [Tmax] of rosuvastatin (ng/mL

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: up to 22 days for part 2

  21. Half-life [t1/2] of rosuvastatin (ng/mL)

    Pharmacokinetic parameters of rosuvastatin and applicable metabolites

    Time frame: up to 22 days for part 2

Other outcomes

  1. Cholesterol

    Monitor plasma cholesterol and 4β-OH-cholesterol levels as a potential CYP3A4 induction marker

    Time frame: up to 23 days for part 1

  2. Cholesterol

    Monitor plasma cholesterol and 4β-OH-cholesterol levels as a potential CYP3A4 induction marker

    Time frame: Up to 22 days for part 1

07

Study locations

1 site
  • PPD Austin Research Unit
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Nov 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Jan 5, 2024
StartActual
Nov 3, 2023
Primary completionActual
Nov 27, 2023
CompletionActual
Dec 4, 2023
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06191991
Lead sponsor
Aligos Therapeutics
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Nov 3, 2023
Primary completion
Nov 27, 2023
Completion
Dec 4, 2023
Last update
Feb 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ALG-055009

Start the discussion